211 related articles for article (PubMed ID: 26339882)
21. Population pharmacokinetic-pharmacodynamic analysis of vernakalant hydrochloride injection (RSD1235) in atrial fibrillation or atrial flutter.
Mao Z; Wheeler JJ; Townsend R; Gao Y; Kshirsagar S; Keirns JJ
J Pharmacokinet Pharmacodyn; 2011 Oct; 38(5):541-62. PubMed ID: 21786177
[TBL] [Abstract][Full Text] [Related]
22. [Vernakalant: a novel antiarrhythmic drug for the rapid conversion of atrial fibrillation to sinus rhythm].
Hirt MN; Eschenhagen T
Dtsch Med Wochenschr; 2010 May; 135(19):971-6. PubMed ID: 20446233
[TBL] [Abstract][Full Text] [Related]
23. Predictors of successful cardioversion with vernakalant in patients with recent-onset atrial fibrillation.
Mochalina N; Juhlin T; Öhlin B; Carlson J; Holmqvist F; Platonov PG
Ann Noninvasive Electrocardiol; 2015 Mar; 20(2):140-7. PubMed ID: 25040826
[TBL] [Abstract][Full Text] [Related]
24. Vernakalant hydrochloride for the rapid conversion of atrial fibrillation after cardiac surgery: a randomized, double-blind, placebo-controlled trial.
Kowey PR; Dorian P; Mitchell LB; Pratt CM; Roy D; Schwartz PJ; Sadowski J; Sobczyk D; Bochenek A; Toft E;
Circ Arrhythm Electrophysiol; 2009 Dec; 2(6):652-9. PubMed ID: 19948506
[TBL] [Abstract][Full Text] [Related]
25. A multicenter, open-label study of vernakalant for the conversion of atrial fibrillation to sinus rhythm.
Stiell IG; Roos JS; Kavanagh KM; Dickinson G
Am Heart J; 2010 Jun; 159(6):1095-101. PubMed ID: 20569725
[TBL] [Abstract][Full Text] [Related]
26. Vernakalant (RSD1235): a novel, atrial-selective antifibrillatory agent.
Fedida D
Expert Opin Investig Drugs; 2007 Apr; 16(4):519-32. PubMed ID: 17371199
[TBL] [Abstract][Full Text] [Related]
27. The new antiarrhythmic drug vernakalant: ex vivo study of human atrial tissue from sinus rhythm and chronic atrial fibrillation.
Wettwer E; Christ T; Endig S; Rozmaritsa N; Matschke K; Lynch JJ; Pourrier M; Gibson JK; Fedida D; Knaut M; Ravens U
Cardiovasc Res; 2013 Apr; 98(1):145-54. PubMed ID: 23341576
[TBL] [Abstract][Full Text] [Related]
28. Efficacy and safety of vernakalant in recent-onset atrial fibrillation after the European medicines agency approval: systematic review and meta-analysis.
Buccelletti F; Iacomini P; Botta G; Marsiliani D; Carroccia A; Gentiloni Silveri N; Franceschi F
J Clin Pharmacol; 2012 Dec; 52(12):1872-8. PubMed ID: 22167572
[TBL] [Abstract][Full Text] [Related]
29. Spotlight on intravenous vernakalant in recent-onset atrial fibrillation.
Duggan ST; Scott LJ
Drugs Aging; 2011 Jun; 28(6):501-4. PubMed ID: 21639409
[TBL] [Abstract][Full Text] [Related]
30. Chemical cardioversion of recent-onset atrial fibrillation in the emergency department using vernakalant hydrochloride achieves safe and rapid restoration of sinus rhythm and facilitates same day discharge.
Stoneman P; Gilligan P; Mahon P; Sheahan R
Ir J Med Sci; 2017 Nov; 186(4):903-908. PubMed ID: 28168639
[TBL] [Abstract][Full Text] [Related]
31. Vernakalant hydrochloride: A novel atrial-selective agent for the cardioversion of recent-onset atrial fibrillation in the emergency department.
Stiell IG; Dickinson G; Butterfield NN; Clement CM; Perry JJ; Vaillancourt C; Calder LA
Acad Emerg Med; 2010 Nov; 17(11):1175-82. PubMed ID: 21175515
[TBL] [Abstract][Full Text] [Related]
32. Novel agents for the acute conversion of atrial fibrillation: focus on vernakalant.
Cialdella P; Pedicino D; Santangeli P
Recent Pat Cardiovasc Drug Discov; 2011 Jan; 6(1):1-8. PubMed ID: 21235460
[TBL] [Abstract][Full Text] [Related]
33. Vernakalant-facilitated electrical cardioversion: comparison of intravenous vernakalant and amiodarone for drug-enhanced electrical cardioversion of atrial fibrillation after failed electrical cardioversion.
Müssigbrodt A; John S; Kosiuk J; Richter S; Hindricks G; Bollmann A
Europace; 2016 Jan; 18(1):51-6. PubMed ID: 26056189
[TBL] [Abstract][Full Text] [Related]
34. Population pharmacokinetics of vernakalant hydrochloride injection (RSD1235) in patients with atrial fibrillation or atrial flutter.
Mao ZL; Townsend RW; Gao Y; Wheeler JJ; Kastrissios H; Keirns J
J Clin Pharmacol; 2012 Jul; 52(7):1042-53. PubMed ID: 21659624
[TBL] [Abstract][Full Text] [Related]
35. Efficacy and Safety of Vernakalant for Cardioversion of Recent-onset Atrial Fibrillation in the Asia-Pacific Region: A Phase 3 Randomized Controlled Trial.
Beatch GN; Bhirangi K; Juul-Moller S; Rustige J
J Cardiovasc Pharmacol; 2017 Feb; 69(2):86-92. PubMed ID: 27828791
[TBL] [Abstract][Full Text] [Related]
36. Vernakalant for cardioversion of recent-onset atrial fibrillation: a systematic review and meta-analysis.
McIntyre WF; Healey JS; Bhatnagar AK; Wang P; Gordon JA; Baranchuk A; Deif B; Whitlock RP; Belley-Côté ÉP
Europace; 2019 Aug; 21(8):1159-1166. PubMed ID: 31292622
[TBL] [Abstract][Full Text] [Related]
37. Vernakalant: RSD 1235, RSD-1235, RSD1235.
Drugs R D; 2007; 8(4):259-65. PubMed ID: 17596113
[TBL] [Abstract][Full Text] [Related]
38. Use of intravenous vernakalant for atrial fibrillation conversion in the regular ward under only bedside monitoring.
Manolis AS; Bethanis S; Metaxa S; Polytarchou K; Sakellaris N; Pyrros I
Hellenic J Cardiol; 2019; 60(1):54-56. PubMed ID: 29454598
[No Abstract] [Full Text] [Related]
39. Efficacy and safety of vernakalant in patients with atrial flutter: a randomized, double-blind, placebo-controlled trial.
Camm AJ; Toft E; Torp-Pedersen C; Vijayaraman P; Juul-Moller S; Ip J; Beatch GN; Dickinson G; Wyse DG;
Europace; 2012 Jun; 14(6):804-9. PubMed ID: 22291438
[TBL] [Abstract][Full Text] [Related]
40. Vernakalant, a mixed sodium and potassium ion channel antagonist that blocks K(v)1.5 channels, for the potential treatment of atrial fibrillation.
Billman GE
Curr Opin Investig Drugs; 2010 Sep; 11(9):1048-58. PubMed ID: 20730700
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]